Reham Khedr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Reham Khedr has a total of 481 co-authors. Here are the top co-authors by number of shared publications:
- Oliver Andreas Cornely
Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging‐Associated Diseases (CECAD), Faculty of Medicine University of Cologne Cologne Germany
4 shared publications - Youssef Madney
Pediatric Oncology Department, Children’s Cancer Hospital Egypt (CCHE-57357), Cairo 11441, Egypt
4 shared publications - Ertan Sal
Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, North Rhine-Westphalia, Germany
3 shared publications - Francesco Marchesi
Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy
3 shared publications - Gustavo-Adolfo Méndez
Department of Medicine, Division of Infectious Diseases, Hospital Escuela De Agudos Dr. Ramón Madariaga , Posadas
3 shared publications - Jon Salmanton-García
Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
3 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Open AccessTreatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- Open Access
- 22 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1540831
Gram-negative blood-stream infections and emerging antimicrobial resistance in children with acute myeloid leukemia during induction chemotherapy at Children’s Cancer Hospital Egypt 57357
Background: In children receiving therapy for acute myeloid leukemia (AML), gram-negative bacteremia is associated with significant morbidity and mortality, especially in the presence of multi-drug resistant [MDR] organisms. objectives: The purpose of this study was to determine the prevalence and antibiotic susceptibility patterns of gram negativebloodstream infections [GNBSI]] during the period of induction chemotherapy [IC] and the associated morbidity and mortality in a large pediatric oncology hospital in a low- middle-income country (LMIC). patients and methods: This is a retrospective analysis of consecutive newly diagnosed patients with acute myeloid leukemia (AML) admitted for induction chemotherapy (IC) from January 2015 to December 2017 at the Children’s Cancer Hospital Egypt 57357. Results: We identified 90[27.4%] children with at least one GNBSI during induction, 72/90[80%] of whom had at least one MDR GNBSI. 124 GNBSI episodes were identified among the ninety children: E.coli 54.8%, K.pneumoniae 16.9%, A.baumannii 6.5%, E.cloacae 4.8%, and P.aeruginosa 4.0%. Thirty-day cumulative infection-related mortality was 27.8% [18.9-37.3%]. Associated morbidity included typhlitis [29/90 (32.2%)], sepsis-related central venous catheter [CVC] removal [12/90 (13.3%)], and admission to intensive care unit [38/90(42%)]. Conclusion: Our study highlights the prevalence of gram-negative bacteria among febrile neutropenic children with AML and the high incidence of antibiotic resistance in our hospital. There is a need for keen surveillance globally of the epidemiology of multi-drug resistant gram-negative organisms and thoughtful studies into antibiotic stewardship to reduce the growing threat of MDR GN infections and the associated morbidity and mortality.
- 22 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1540831
Open AccessGram-negative blood-stream infections and emerging antimicrobial resistance in children with acute myeloid leukemia during induction chemotherapy at Children’s Cancer Hospital Egypt 57357
Background: In children receiving therapy for acute myeloid leukemia (AML), gram-negative bacteremia is associated with significant morbidity and mortality, especially in the presence of multi-drug resistant [MDR] organisms. objectives: The purpose of this study was to determine the prevalence and antibiotic susceptibility patterns of gram negativebloodstream infections [GNBSI]] during the period of induction chemotherapy [IC] and the associated morbidity and mortality in a large pediatric oncology hospital in a low- middle-income country (LMIC). patients and methods: This is a retrospective analysis of consecutive newly diagnosed patients with acute myeloid leukemia (AML) admitted for induction chemotherapy (IC) from January 2015 to December 2017 at the Children’s Cancer Hospital Egypt 57357. Results: We identified 90[27.4%] children with at least one GNBSI during induction, 72/90[80%] of whom had at least one MDR GNBSI. 124 GNBSI episodes were identified among the ninety children: E.coli 54.8%, K.pneumoniae 16.9%, A.baumannii 6.5%, E.cloacae 4.8%, and P.aeruginosa 4.0%. Thirty-day cumulative infection-related mortality was 27.8% [18.9-37.3%]. Associated morbidity included typhlitis [29/90 (32.2%)], sepsis-related central venous catheter [CVC] removal [12/90 (13.3%)], and admission to intensive care unit [38/90(42%)]. Conclusion: Our study highlights the prevalence of gram-negative bacteria among febrile neutropenic children with AML and the high incidence of antibiotic resistance in our hospital. There is a need for keen surveillance globally of the epidemiology of multi-drug resistant gram-negative organisms and thoughtful studies into antibiotic stewardship to reduce the growing threat of MDR GN infections and the associated morbidity and mortality.
- Open Access
- 27 February 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (3)
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry
Background: Human metapneumovirus (hMPV) is an increasingly recognized respiratory pathogen in immunocompromised patients, but its impact in haematological malignancies is poorly defined. Unlike influenza or SARS-CoV-2, hMPV has no specific treatment or vaccine, contributing to underdiagnosis and underestimation of its clinical relevance. Method: We performed a multicentre retrospective cohort study within the Epidemiology of COVID-19 in patients with hematological malignancies: A European Haematology Association Survey/ Epidemiology of respiratory viral infections in patients with hematological malignancies: A European Haematology Association Survey registry of haematological patients with hMPV (January 2023–December 2024), comparing clinical features and outcomes with matched influenza and SARS-CoV-2 cohorts. Results: The study included 130 patients with hMPV. Median age was 58.5 years; 57% were male. Plasma cell neoplasms (25%), lymphoma (23%), and acute myeloid leukemia (20%) were the most common hematological malignancies. Hospitalization occurred in 64%, intensive care unit (ICU) admission in 19%, and 30-day mortality was 8%. Most cases (73%) received supportive care only. Secondary infections were common (24%). Chronic renal disease significantly increased mortality risk (hazard ratio 20.9 11.05, P = .014). Compared with influenza and SARS-CoV-2, hMPV patients had comparable severity and outcomes, with 18.5% ICU admission rates versus 25.9% for influenza (P = .316) and 20.9% versus 4.7% for SARS-CoV-2 (P = .006), and 30-day mortality of 5.6% versus 11.1% for influenza (P = .489) and 7.0% versus 2.3% for SARS-CoV-2 (P = .277), yet received fewer targeted interventions. Conclusions: hMPV causes clinically significant disease in patients with hematological malignancy, often necessitating hospital and ICU care, and leading to mortality. In the absence of specific treatments or vaccines, this virus remains an underrecognized pathogen in patients with hematological malignancy. Enhanced clinical awareness and investment in diagnostics, prevention, and therapeutics are needed.
- 27 February 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (3)
Open AccessUnderrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry
Background: Human metapneumovirus (hMPV) is an increasingly recognized respiratory pathogen in immunocompromised patients, but its impact in haematological malignancies is poorly defined. Unlike influenza or SARS-CoV-2, hMPV has no specific treatment or vaccine, contributing to underdiagnosis and underestimation of its clinical relevance. Method: We performed a multicentre retrospective cohort study within the Epidemiology of COVID-19 in patients with hematological malignancies: A European Haematology Association Survey/ Epidemiology of respiratory viral infections in patients with hematological malignancies: A European Haematology Association Survey registry of haematological patients with hMPV (January 2023–December 2024), comparing clinical features and outcomes with matched influenza and SARS-CoV-2 cohorts. Results: The study included 130 patients with hMPV. Median age was 58.5 years; 57% were male. Plasma cell neoplasms (25%), lymphoma (23%), and acute myeloid leukemia (20%) were the most common hematological malignancies. Hospitalization occurred in 64%, intensive care unit (ICU) admission in 19%, and 30-day mortality was 8%. Most cases (73%) received supportive care only. Secondary infections were common (24%). Chronic renal disease significantly increased mortality risk (hazard ratio 20.9 11.05, P = .014). Compared with influenza and SARS-CoV-2, hMPV patients had comparable severity and outcomes, with 18.5% ICU admission rates versus 25.9% for influenza (P = .316) and 20.9% versus 4.7% for SARS-CoV-2 (P = .006), and 30-day mortality of 5.6% versus 11.1% for influenza (P = .489) and 7.0% versus 2.3% for SARS-CoV-2 (P = .277), yet received fewer targeted interventions. Conclusions: hMPV causes clinically significant disease in patients with hematological malignancy, often necessitating hospital and ICU care, and leading to mortality. In the absence of specific treatments or vaccines, this virus remains an underrecognized pathogen in patients with hematological malignancy. Enhanced clinical awareness and investment in diagnostics, prevention, and therapeutics are needed.
- Open Access
Changes in Gut Microbial Diversity and Correlation with Clinical Outcome in Children with Acute Myeloid Leukemia Receiving Induction Chemotherapy
Background: The gut microbiome affects human health, and patients with cancer are no exception. In those patients, intensive chemotherapy impairs gut barrier integrity, causing dysbiosis, bacterial translocation, and higher infection risk. Objectives: This prospective study, conducted at Children’s Cancer Hospital in Egypt, profiles the microbiome of 29 pediatric patients with AML, and examines how induction chemotherapy and antibiotics affect their microbiome. Methods: Gut microbiome changes were evaluated before treatment (T1), then 7 (T2) and 21–28 days (T3) from induction start. Microbial DNA, extracted from rectal swabs or stool samples, was subjected to 16S rRNA amplicon sequencing, followed by bioinformatics and statistical analyses. Results: Treatment significantly decreased the richness and Shannon diversity of the gut microbiome and caused dysbiosis that was only partially restored at T3. Whereas Firmicutes remained the most abundant phylum throughout, Actinobacteria significantly decreased in abundance after treatment. Proteobacteria had their lowest abundance at T3, while Verrucomicrobacteria were relatively abundant at T1 but undetectable by T3. The abundance of Enterococcus and Klebsiella was associated with stool culture results, and the Proteobacteria-to-Firmicutes ratio was associated with treatment. Conclusions: Gut microbial diversity declined in patients during induction chemotherapy, with a strong association of microbial composition with stool culture results but not with bacteremia.
Open AccessChanges in Gut Microbial Diversity and Correlation with Clinical Outcome in Children with Acute Myeloid Leukemia Receiving Induction Chemotherapy
Background: The gut microbiome affects human health, and patients with cancer are no exception. In those patients, intensive chemotherapy impairs gut barrier integrity, causing dysbiosis, bacterial translocation, and higher infection risk. Objectives: This prospective study, conducted at Children’s Cancer Hospital in Egypt, profiles the microbiome of 29 pediatric patients with AML, and examines how induction chemotherapy and antibiotics affect their microbiome. Methods: Gut microbiome changes were evaluated before treatment (T1), then 7 (T2) and 21–28 days (T3) from induction start. Microbial DNA, extracted from rectal swabs or stool samples, was subjected to 16S rRNA amplicon sequencing, followed by bioinformatics and statistical analyses. Results: Treatment significantly decreased the richness and Shannon diversity of the gut microbiome and caused dysbiosis that was only partially restored at T3. Whereas Firmicutes remained the most abundant phylum throughout, Actinobacteria significantly decreased in abundance after treatment. Proteobacteria had their lowest abundance at T3, while Verrucomicrobacteria were relatively abundant at T1 but undetectable by T3. The abundance of Enterococcus and Klebsiella was associated with stool culture results, and the Proteobacteria-to-Firmicutes ratio was associated with treatment. Conclusions: Gut microbial diversity declined in patients during induction chemotherapy, with a strong association of microbial composition with stool culture results but not with bacteremia.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400182
Cost-Effectiveness of Oral Levofloxacin Versus Amoxicillin-Clavulanate/Ciprofloxacin for Outpatient Management of Low-Risk Febrile Neutropenia in Children With Cancer in Egypt
PURPOSE: Febrile neutropenia (FN) is a common cancer complication in children. A growing body of evidence suggests that home-based care with oral antibiotics is safe and effective in carefully selected children with low-risk (LR) FN. This study aimed to assess the efficacy and safety of oral levofloxacin versus oral amoxicillin-clavulanate/ciprofloxacin in the management of LR-FN in children with cancer over a time horizon of 7 days from the National Cancer Institute (NCI) perspective. PATIENTS AND METHODS: This is a randomized controlled study conducted at the NCI from December 2021 to September 2022, including children and adolescents age between 3 and 18 years who presented to the emergency room with LR-FN criteria with the exclusion of patients younger than 3 years and patients with Down syndrome. One hundred LR-FN episodes were enrolled in each arm. Patient demographics, microbiologic data, and outcomes were collected at different time points. A decision analytic model was created to compare the two treatment strategies. The outcome measures included quality-adjusted FN episodes, costs, and incremental cost-effectiveness ratios. RESULTS: Levofloxacin was a safe and effective treatment option for LR-FN. It proved to be the dominant strategy against amoxicillin-clavulanate/ciprofloxacin with an incremental quality-adjusted life-year (QALY) of 0.0001 and a lower cost of 62.4996 Egyptian pounds (EGPs) in the treatment of home-based LR-FN with a willingness to pay a threshold of 77,520 EGPs per QALY (1 gross domestic product/capita). CONCLUSION: For the treatment of FN in pediatric patients with cancer, levofloxacin offers a cost-saving option with improved survival benefits over a 7-day time horizon from the NCI perspective. These findings will help health care decisions regarding the allocation of health care system resources to improve supportive care for patients with LR-FN.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2400182
Cost-Effectiveness of Oral Levofloxacin Versus Amoxicillin-Clavulanate/Ciprofloxacin for Outpatient Management of Low-Risk Febrile Neutropenia in Children With Cancer in Egypt
PURPOSE: Febrile neutropenia (FN) is a common cancer complication in children. A growing body of evidence suggests that home-based care with oral antibiotics is safe and effective in carefully selected children with low-risk (LR) FN. This study aimed to assess the efficacy and safety of oral levofloxacin versus oral amoxicillin-clavulanate/ciprofloxacin in the management of LR-FN in children with cancer over a time horizon of 7 days from the National Cancer Institute (NCI) perspective. PATIENTS AND METHODS: This is a randomized controlled study conducted at the NCI from December 2021 to September 2022, including children and adolescents age between 3 and 18 years who presented to the emergency room with LR-FN criteria with the exclusion of patients younger than 3 years and patients with Down syndrome. One hundred LR-FN episodes were enrolled in each arm. Patient demographics, microbiologic data, and outcomes were collected at different time points. A decision analytic model was created to compare the two treatment strategies. The outcome measures included quality-adjusted FN episodes, costs, and incremental cost-effectiveness ratios. RESULTS: Levofloxacin was a safe and effective treatment option for LR-FN. It proved to be the dominant strategy against amoxicillin-clavulanate/ciprofloxacin with an incremental quality-adjusted life-year (QALY) of 0.0001 and a lower cost of 62.4996 Egyptian pounds (EGPs) in the treatment of home-based LR-FN with a willingness to pay a threshold of 77,520 EGPs per QALY (1 gross domestic product/capita). CONCLUSION: For the treatment of FN in pediatric patients with cancer, levofloxacin offers a cost-saving option with improved survival benefits over a 7-day time horizon from the NCI perspective. These findings will help health care decisions regarding the allocation of health care system resources to improve supportive care for patients with LR-FN.
- Open Access
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 288-295
Successful Management of Pediatric Patients with Low-Risk Febrile Neutropenia Using a Clinical Care Pathway in Egypt
Khedr RA, et al. Infect Chemother. 2025 Apr;57:e24. https://doi.org/10.3947/ic.2025.0009
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 288-295
Open AccessSuccessful Management of Pediatric Patients with Low-Risk Febrile Neutropenia Using a Clinical Care Pathway in Egypt
Khedr RA, et al. Infect Chemother. 2025 Apr;57:e24. https://doi.org/10.3947/ic.2025.0009
- Open Access
Factors affecting mortality in COVID-19-associated pulmonary aspergillosis: An international ID-IRI study
- Open Access
- 31 January 2024
- Published by Wiley
Clinical Characteristics and Outcome of Invasive Mould Sinusitis in Children with Hematological Malignancies
Background: Pediatric patients with hematologic malignancies are susceptible to invasive mould sinusitis (IMS). IMS is a rare entity that requires careful attention and prompts management due to its high mortality. Methods: This is a retrospective analysis of pediatric patients with hematological malignancies treated at Children Cancer Hospital Egypt through the period from 2008 till 2016 with proven IMS. Results: Thirty-four patients were diagnosed with IMS. Five 5(15%) patients had an invasive rhino-cerebral fungal disease. Mucormycosis were isolated in 17(50%) patients, Aspergillosis in 13 (38%) patients, and mixed fungal in 4 (12%) patients. Sinuses were the only localized site in (45%). Extra-nasal spread was reported in 20 patients; Sino-pulmonary in 12(35%), Sino-cerebral in 5(15%), and Sino-orbital in 2(5%) patients. Combined antifungal therapy with surgical debridement was done in 59% of patients with a better outcome when compared to those who received only medical antifungal treatment (P = 0.01). The overall mortality rate at week 12 was 35% (12 patients), and IMS attributable mortality was 20% (7 patients). IMS with cerebral extension carried the highest mortality rate for both 12-week all-cause (p=0.04) and fungal-attributable (P=0.01) mortality. Conclusions: Pediatric patients with hematologic malignancies are susceptible to invasive mould sinusitis (IMS). Surgical debridement, combined with antifungal therapy, improves outcomes among those patients. IMS patients with cerebral extension had a higher risk of mortality.
- 31 January 2024
- Published by Wiley
Open AccessClinical Characteristics and Outcome of Invasive Mould Sinusitis in Children with Hematological Malignancies
Background: Pediatric patients with hematologic malignancies are susceptible to invasive mould sinusitis (IMS). IMS is a rare entity that requires careful attention and prompts management due to its high mortality. Methods: This is a retrospective analysis of pediatric patients with hematological malignancies treated at Children Cancer Hospital Egypt through the period from 2008 till 2016 with proven IMS. Results: Thirty-four patients were diagnosed with IMS. Five 5(15%) patients had an invasive rhino-cerebral fungal disease. Mucormycosis were isolated in 17(50%) patients, Aspergillosis in 13 (38%) patients, and mixed fungal in 4 (12%) patients. Sinuses were the only localized site in (45%). Extra-nasal spread was reported in 20 patients; Sino-pulmonary in 12(35%), Sino-cerebral in 5(15%), and Sino-orbital in 2(5%) patients. Combined antifungal therapy with surgical debridement was done in 59% of patients with a better outcome when compared to those who received only medical antifungal treatment (P = 0.01). The overall mortality rate at week 12 was 35% (12 patients), and IMS attributable mortality was 20% (7 patients). IMS with cerebral extension carried the highest mortality rate for both 12-week all-cause (p=0.04) and fungal-attributable (P=0.01) mortality. Conclusions: Pediatric patients with hematologic malignancies are susceptible to invasive mould sinusitis (IMS). Surgical debridement, combined with antifungal therapy, improves outcomes among those patients. IMS patients with cerebral extension had a higher risk of mortality.
- Open Access
- 17 February 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (2) , 405
Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome
Carbapenem-resistant Enterobacteriaceae (CRE) is an important emerging threat among pediatric cancer patients, with a high mortality rate. This retrospective study included all pediatric cancer patients with (CRE) bloodstream infections (BSIs) at a children’s cancer hospital in Egypt (2013–2017). Two hundred and fifty-four pediatric cancer patients with CRE BSI were identified; 74% had hematological malignancies, and 26% had solid tumors. Acute myeloid leukemia was the most common hematological malignancy (50%). The main clinical features for acquiring CRE-BSI were previous antibiotics exposure (90%), profound neutropenia (84%), prolonged steroid use (45%), previous colonization with a resistant pathogen (35%), ICU admission within 90 days (28%), and central venous catheter use (24%). E. coli was the most common isolated pathogen (56%), followed by Klebsiella pneumoniae (37%). All isolates were resistant to carbapenem with an MIC < 4–8 μg/mL in 100 (45%) and >8 μg/mL in 153 (55%). The overall mortality rate was 57%, and 30 day mortality was reported in 30%. Upon multivariate analysis, for the patients with Klebsiella pneumoniae BSI, carbapenem resistance with an MIC > 8 μg/mL and associated typhlitis or pneumonia were predictors of poor outcome. In conclusion, CRE-BSI is a major threat among pediatric cancer patients in limited resource countries with limited options for treatment. Antimicrobial stewardship for early detection through routine screening, adequate empirical treatment, and timely adequate therapy may impact the outcome for such high-risk patient groups.
- 17 February 2023
- Published by MDPI AG in Antibiotics
- Vol. 12 (2) , 405
Open AccessCarbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome
Carbapenem-resistant Enterobacteriaceae (CRE) is an important emerging threat among pediatric cancer patients, with a high mortality rate. This retrospective study included all pediatric cancer patients with (CRE) bloodstream infections (BSIs) at a children’s cancer hospital in Egypt (2013–2017). Two hundred and fifty-four pediatric cancer patients with CRE BSI were identified; 74% had hematological malignancies, and 26% had solid tumors. Acute myeloid leukemia was the most common hematological malignancy (50%). The main clinical features for acquiring CRE-BSI were previous antibiotics exposure (90%), profound neutropenia (84%), prolonged steroid use (45%), previous colonization with a resistant pathogen (35%), ICU admission within 90 days (28%), and central venous catheter use (24%). E. coli was the most common isolated pathogen (56%), followed by Klebsiella pneumoniae (37%). All isolates were resistant to carbapenem with an MIC < 4–8 μg/mL in 100 (45%) and >8 μg/mL in 153 (55%). The overall mortality rate was 57%, and 30 day mortality was reported in 30%. Upon multivariate analysis, for the patients with Klebsiella pneumoniae BSI, carbapenem resistance with an MIC > 8 μg/mL and associated typhlitis or pneumonia were predictors of poor outcome. In conclusion, CRE-BSI is a major threat among pediatric cancer patients in limited resource countries with limited options for treatment. Antimicrobial stewardship for early detection through routine screening, adequate empirical treatment, and timely adequate therapy may impact the outcome for such high-risk patient groups.
- Open Access
- 15 August 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (8) , 850
COVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience
Patients with COVID-19 are at risk of developing secondary complications such as invasive pulmonary aspergillosis and mucormycosis. This is a retrospective study including all cancer children diagnosed with COVID-19-associated pulmonary fungal infection (CAPFI) during the period 2020–2021. A total of 200 patients were diagnosed with COVID-19, out of which 21 (10%) patients were diagnosed with CAPFI, 19 patients (90%) with COVID-aspergillosis (CAPA), and 2 (10%) patients with COVID-mucormycosis (CAM). Patients with CAPFI were classified using the “2020 ECMM/ISHAM consensus criteria”; proven in 2 (10%) patients, probable in 12 (57%), and possible in 7 (33%) patients. Although the hematological malignancy patients were already on antifungal prophylaxis, breakthrough fungal infection was reported in 16/21 (75%), 14 (65%) patients had CAPA while on echinocandin prophylaxis, while 2 (10%) patients had CAM while on voriconazole prophylaxis. Overall mortality was reported in 8 patients (38%) while CAPFI-attributable mortality was reported in 4 patients (20%). In conclusion, clinicians caring for pediatric cancer patients with COVID-19 should consider invasive pulmonary fungal infection, even if they are on antifungal prophylaxis, especially with worsening of the clinical chest condition. A better understanding of risk factors for adverse outcomes may improve clinical management in these patients.
- 15 August 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (8) , 850
Open AccessCOVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience
Patients with COVID-19 are at risk of developing secondary complications such as invasive pulmonary aspergillosis and mucormycosis. This is a retrospective study including all cancer children diagnosed with COVID-19-associated pulmonary fungal infection (CAPFI) during the period 2020–2021. A total of 200 patients were diagnosed with COVID-19, out of which 21 (10%) patients were diagnosed with CAPFI, 19 patients (90%) with COVID-aspergillosis (CAPA), and 2 (10%) patients with COVID-mucormycosis (CAM). Patients with CAPFI were classified using the “2020 ECMM/ISHAM consensus criteria”; proven in 2 (10%) patients, probable in 12 (57%), and possible in 7 (33%) patients. Although the hematological malignancy patients were already on antifungal prophylaxis, breakthrough fungal infection was reported in 16/21 (75%), 14 (65%) patients had CAPA while on echinocandin prophylaxis, while 2 (10%) patients had CAM while on voriconazole prophylaxis. Overall mortality was reported in 8 patients (38%) while CAPFI-attributable mortality was reported in 4 patients (20%). In conclusion, clinicians caring for pediatric cancer patients with COVID-19 should consider invasive pulmonary fungal infection, even if they are on antifungal prophylaxis, especially with worsening of the clinical chest condition. A better understanding of risk factors for adverse outcomes may improve clinical management in these patients.